Arai H - Search Results

1

Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease.

Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, Muramatsu S, Ozawa K, Saido TC, Arai H, Sasaki H. Maruyama M, et al. Among authors: arai h. Ann Neurol. 2005 Jun;57(6):832-42. doi: 10.1002/ana.20494. Ann Neurol. 2005. PMID: 15929037

2

Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.

Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, Arai H, Sasaki H. Maruyama M, et al. Among authors: arai h. Arch Neurol. 2004 May;61(5):716-20. doi: 10.1001/archneur.61.5.716. Arch Neurol. 2004. PMID: 15148149

3

Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease.

Matsui T, Nemoto M, Maruyama M, Yuzuriha T, Yao H, Tanji H, Ootsuki M, Tomita N, Matsushita S, Higuchi S, Yoshida Y, Seki T, Iwasaki K, Furukawa K, Arai H. Matsui T, et al. Among authors: arai h. Neurodegener Dis. 2005;2(6):299-304. doi: 10.1159/000092316. Neurodegener Dis. 2005. PMID: 16909012

4

A practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease.

Matsui T, Higuchi M, Okamura N, Arai H, Sasaki H. Matsui T, et al. Among authors: arai h. Neurology. 1999 Dec 10;53(9):2208-9. doi: 10.1212/wnl.53.9.2208. Neurology. 1999. PMID: 10599813 No abstract available.

5

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H. Maruyama M, et al. Among authors: arai h. Exp Neurol. 2001 Dec;172(2):433-6. doi: 10.1006/exnr.2001.7814. Exp Neurol. 2001. PMID: 11716567

6

Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression.

Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H. Ohrui T, et al. Among authors: arai h. Neurology. 2004 Oct 12;63(7):1324-5. doi: 10.1212/01.wnl.0000140705.23869.e9. Neurology. 2004. PMID: 15477567 Clinical Trial. No abstract available.

7

ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease.

He M, Ohrui T, Maruyama M, Tomita N, Nakayama K, Higuchi M, Furukawa K, Arai H. He M, et al. Among authors: arai h. Neurology. 2006 Oct 10;67(7):1309-10. doi: 10.1212/01.wnl.0000238102.04582.ec. Neurology. 2006. PMID: 17030780 No abstract available.

8

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.

Arai H, Higuchi S, Sasaki H. Arai H, et al. Gerontology. 1997;43 Suppl 1:2-10. doi: 10.1159/000213879. Gerontology. 1997. PMID: 9187933 Review.

9

Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H. Okamura N, et al. Among authors: arai h. Am J Psychiatry. 2002 Mar;159(3):474-6. doi: 10.1176/appi.ajp.159.3.474. Am J Psychiatry. 2002. PMID: 11870015

10

Neuroanatomical correlates of low body weight in Alzheimer's disease: a PET study.

Hu X, Okamura N, Arai H, Higuchi M, Maruyama M, Itoh M, Yamaguchi K, Sasaki H. Hu X, et al. Among authors: arai h. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1285-9. doi: 10.1016/s0278-5846(02)00291-9. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 12502015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,760 results

Search Page

Filters